Previous close | 202.54 |
Open | 202.54 |
Bid | 193.20 x 800 |
Ask | 202.29 x 1000 |
Day's range | 198.10 - 203.32 |
52-week range | 187.16 - 468.55 |
Volume | |
Avg. volume | 1,095,843 |
Market cap | 29.636B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | 20.71 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
If you want to know who really controls Biogen Inc. ( NASDAQ:BIIB ), then you'll have to look at the makeup of its...
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.